Celldex Therapeutics, Inc. — Director's Dealing 2022

Jun 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2022-06-16

Reporting Person: Crowley Elizabeth (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-16	Incentive Stock Option (right to buy)	$22.48	A	77000	Acquired	2032-06-16	Common Stock (77000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.